Candriam SCA’s GSK GSK Stock Holding History

Candriam SCA’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-76	Closed	-$4K	–	797
2022 Q1	$4K	Buy	+76	New	+$4.13K	﹤0.01%	786
2021 Q4	–	Sell	-74	Closed	-$4K	–	826
2021 Q3	$4K	Hold	74	–	–	﹤0.01%	857
2021 Q2	$4K	Sell	74 -4	-5%	-$192	﹤0.01%	859
2021 Q1	$3K	Buy	78 +46	+144%	+$2.09K	﹤0.01%	781
2020 Q4	$1K	Buy	32 +18	+129%	+$827	﹤0.01%	802
2020 Q3	$1K	Hold	14	–	–	﹤0.01%	798
2020 Q2	$1K	Buy	+14	New	+$718	﹤0.01%	794
2018 Q4	–	Sell	-57	Closed	-$3K	–	826
2018 Q3	$3K	Buy	57 +2	+4%	+$102	﹤0.01%	790
2018 Q2	$3K	Buy	+55	New	+$2.77K	﹤0.01%	771

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Candriam SCA's GSK Position: Q2 2022 in Review

Candriam SCA sold out of GSK (GSK) in Q2 2022, closing a stake of 76 shares — an estimated $4K sold.

Candriam SCA first reported a position in GSK in Q2 2018 and held it in 9 quarters. The position peaked at $4K in Q1 2022. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

Candriam SCA reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
Candriam SCA sold 76 GSK shares in Q2 2022, an estimated $4K.
Candriam SCA first reported a position in GSK in Q2 2018 and held it in 9 quarters.
Candriam SCA's GSK position peaked at $4K in Q1 2022.
900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Candriam SCA's 13F filing for Q2 2022, filed 3 Aug 2022.